Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Malka

Showing results (81-90 of 192) with videos related to

Pageof 20
Sort By:
Bulletin Du Cancer|July 1, 2014
[A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker]Marie Wislez, David Malka, Jaafar Bennouna, et al.
Anti-Cancer Drugs|December 12, 2018
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathyAlice Boilève, Camille Wicker, Benjamin Verret, et al.
Oncology|January 25, 2012
Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter studyMaximilien Barret, David Malka, Thomas Aparicio, et al.
Annals of Surgical Oncology|August 30, 2017
Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional ChemotherapyFlorence Le Roy, Maximiliano Gelli, Antoine Hollebecque, et al.
BMJ Open|November 21, 2022
Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trialJean-Baptiste Trouiller, Bérengère Macabeo, Andrew Poll, et al.
Bulletin Du Cancer|December 9, 2022
[Prophylaxis and management of cancer-associated thrombosis: Practical issues about anticoagulant use]David Malka, Nicolas Girard, David M Smadja, et al.
Frontiers in Oncology|July 3, 2024
Case report: Microsatellite instability determination is not always black and white in Lynch syndrome diagnosisJulieta E Rodriguez, Damien Vasseur, Mohamed Amine Bani, et al.
Bulletin Du Cancer|December 19, 2022
Matthieu Delaye, Eric Assenat, Emmanuel Boleslawski, et al.
Cancer Treatment and Research Communications|December 24, 2022
Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatmentEugénie Rigault, Benjamin Lacas, Olivier Glehen, et al.
Nature Clinical Practice. Oncology|March 20, 2008
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapyYohann Loriot, Gabriel Perlemuter, David Malka, et al.
Pageof 20

Showing results (81-90 of 192) with videos related to

Sort By:
Pageof 20
Bulletin Du Cancer|July 1, 2014
[A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker]Marie Wislez, David Malka, Jaafar Bennouna, et al.
Anti-Cancer Drugs|December 12, 2018
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathyAlice Boilève, Camille Wicker, Benjamin Verret, et al.
Oncology|January 25, 2012
Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter studyMaximilien Barret, David Malka, Thomas Aparicio, et al.
Annals of Surgical Oncology|August 30, 2017
Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional ChemotherapyFlorence Le Roy, Maximiliano Gelli, Antoine Hollebecque, et al.
BMJ Open|November 21, 2022
Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trialJean-Baptiste Trouiller, Bérengère Macabeo, Andrew Poll, et al.
Bulletin Du Cancer|December 9, 2022
[Prophylaxis and management of cancer-associated thrombosis: Practical issues about anticoagulant use]David Malka, Nicolas Girard, David M Smadja, et al.
Frontiers in Oncology|July 3, 2024
Case report: Microsatellite instability determination is not always black and white in Lynch syndrome diagnosisJulieta E Rodriguez, Damien Vasseur, Mohamed Amine Bani, et al.
Bulletin Du Cancer|December 19, 2022
Matthieu Delaye, Eric Assenat, Emmanuel Boleslawski, et al.
Cancer Treatment and Research Communications|December 24, 2022
Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatmentEugénie Rigault, Benjamin Lacas, Olivier Glehen, et al.
Nature Clinical Practice. Oncology|March 20, 2008
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapyYohann Loriot, Gabriel Perlemuter, David Malka, et al.
Pageof 20